As per MRFR analysis, the Japan Diabetic Retinopathy Market Size was estimated at 344.8 (USD Million) in 2023. The Japan Diabetic Retinopathy Market is expected to grow from 362 (USD Million) in 2024 to 912 (USD Million) by 2035. The Japan Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 8.763% during the forecast period (2025 - 2035).
The Ministry of Health, Labour, and Welfare has noted that the country's expanding diabetes incidence is driving significant trends in the Japanese diabetic retinopathy market. Early detection and good management of diabetic retinopathy, a major cause of blindness among working-age adults in Japan, are more important as the number of people with diabetes diagnoses rises.
This situation is a major market driver that forces technology firms and healthcare providers to embrace cutting-edge screening methods and creative treatment approaches. Additionally, telemedicine and mobile health applications are being developed to explore market prospects.
These technologies make screening services more accessible, particularly in remote locations where there may be a shortage of medical experts. As more patients look for individualized treatment programs that address their unique needs, the emphasis on patient-centered care is also growing.
Such programs, which promote research and cooperation among stakeholders in the healthcare industry, are being supported by the Japanese government. Artificial intelligence has been increasingly used into diabetic retinopathy diagnosis techniques in recent years.
By enabling faster, more accurate assessments, these developments lessen the workload for ophthalmologists and increase the accuracy of imaging technologies. Effective disease management also much depends on the development of novel treatments, such as anti-VEGF injections.
In a country marked by an ageing population and rising healthcare expenses, this modernisation is crucial to meeting the growing need for effective, efficient care solutions. All things considered, these patterns reflect a dynamic change in the Japanese market for diabetic retinopathy, which is being fuelled by the demand for improved technology and a more all-encompassing method of patient treatment.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The alarming rise in diabetes prevalence in Japan is a significant driver for the Japan Diabetic Retinopathy Market. According to statistics from the Ministry of Health, Labour and Welfare of Japan, around 7.4 million people were reported to have diabetes in recent years, marking a steady increase of approximately 10 percent over the last decade.
This statistic underscores how the growing diabetic population is likely to lead to higher occurrences of diabetic retinopathy, subsequently propelling market demand for diagnosis and treatment options. Research and Development (R&D) efforts in innovative treatment solutions are essential to manage the condition effectively.
Companies like Takeda Pharmaceutical Company Limited are actively involved in developing new therapeutic drugs aimed at managing diabetes and its complications, which in turn fuels the growth of the Japan Diabetic Retinopathy Market.
Technological advancements in the field of ophthalmology are significantly driving the Japan Diabetic Retinopathy Market. The adoption of innovative devices such as Optical Coherence Tomography (OCT) and AI-driven imaging tools have demonstrated improved accuracy in diagnosing diabetic retinopathy.
A recent report indicated that these advanced imaging techniques could reduce the need for invasive procedures by more than 20 percent, thus streamlining the diagnosis process. Leading organizations, such as the Japan Retina Society, have also endorsed and promoted the use of such technological advancements, highlighting their impact on early detection and treatment of diabetic retinopathy.
The Japanese government is actively investing in healthcare initiatives aimed at combating diabetes and its complications, including diabetic retinopathy. Programs like the 'National Health Promotion Movement in the 21st Century' have facilitated increased awareness and early screening for diabetes-related eye conditions.
Under this initiative, a 30 percent growth in screening programs has been observed over the last five years, according to reports from the Ministry of Health, Labour and Welfare. These efforts not only enhance public awareness but also create a conducive environment for companies within the Japan Diabetic Retinopathy Market to thrive, thereby fueling market growth.
The Japan Diabetic Retinopathy Market is characterized by its crucial Type segmentation, which can be divided into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). This segmentation plays a vital role in addressing the increasing prevalence of diabetic retinopathy, a significant concern considering Japan's aging population and rising cases of diabetes.
NPDR is notable for being the early stage of the disease, wherein the retina experiences no new blood vessel growth but may exhibit symptoms like microaneurysms and retinal hemorrhages. This stage is critical as timely detection and management can significantly alter the disease's trajectory, preventing progression to more severe forms.
On the other hand, PDR represents a more advanced condition characterized by abnormal blood vessel proliferation, which can lead to serious complications like vision loss. The growing awareness of diabetic eye diseases and enhanced screening programs in Japan underline the significance of both NPDR and PDR.
The continuous advancements in diagnostic technologies, along with the development of innovative treatment methods, support patient management effectively, addressing the needs of a substantial demographic suffering from diabetes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment segment of the Japan Diabetic Retinopathy Market is crucial in addressing the increasing prevalence of this ocular complication among diabetic patients in Japan. Pharmacological Therapies are significant for managing symptoms and slowing disease progression, while Laser Treatment remains a primary choice due to its effectiveness in preventing severe vision loss.
Surgery is often considered for advanced cases where previous treatments have failed, highlighting the critical role of each approach in the overall treatment landscape. The integration of new technologies and techniques in Laser Treatment and Surgical options is expected to enhance effectiveness, driving the market forward.
As Japan continues to confront rising diabetes rates, the demand for effective treatment options will rise, emphasizing the importance of this segment in safeguarding visual health.
The Japan Diabetic Retinopathy Market data indicates an increasing recognition of the unique needs of this demographic, calling for innovative solutions to mitigate the burden of diabetic retinopathy on patients and healthcare systems alike.
With advancements in Research and Development, the Treatment segment is poised for significant growth, offering both challenges and opportunities in the evolving landscape of diabetic eye disease management.
The End-user segment of the Japan Diabetic Retinopathy Market reveals crucial insights into its structure and functionalities, dominating areas crucial for managing this ocular condition. Hospitals and Clinics serve as the primary settings for diagnosis and treatment, showcasing their essential role in providing comprehensive care and access to advanced therapeutic technologies.
Ophthalmology Centers specialize in eye care, focusing solely on vision-related diseases, which positions them as significant players in screening and treatment techniques tailored to diabetic retinopathy. Research Institutes contribute by driving innovation through clinical research and studies aimed at improving treatment methods.
In Japan, a rapidly aging population and increasing diabetes prevalence reinforce the importance of these End-users. Collectively, this segment reflects vital attributes of the Japan Diabetic Retinopathy Market, facilitating better healthcare delivery and improving patient outcomes.
The Japan Diabetic Retinopathy Market is characterized by a competitive landscape that is evolving rapidly due to advancements in technology, a growing awareness of diabetic eye diseases, and the increasing prevalence of diabetes within the population.
This market features a mix of established pharmaceutical companies and emerging firms, all striving to innovate and capture market share by developing better therapeutic options, treatment protocols, and diagnostic tools.
Key players in the sector are continuously exploring collaborations, strategic partnerships, and mergers to enhance their product portfolios and improve patient outcomes. The competitive edge in this market heavily relies on R&D capabilities, market reach, and the ability to address unmet medical needs effectively.
Santen Pharmaceutical has established a notable presence in the Japan Diabetic Retinopathy Market, primarily focusing on the development and commercialization of therapies targeting ocular diseases, including diabetic retinopathy.
The company's strengths lie in its robust R&D framework dedicated to advancing therapeutic options for eye health, making it a crucial player in this sector. Santen Pharmaceutical excels in its commitment to innovation and the application of cutting-edge technologies, enabling the delivery of effective treatment modalities.
Their localized understanding of the Japanese healthcare landscape ensures that their products meet specific regulatory requirements and patient needs, thereby enhancing trust and loyalty within the market.
Bayer also holds a significant position in the Japan Diabetic Retinopathy Market, known for its contributions in the field of ophthalmology. The company's portfolio includes several key products aimed at treating diabetic retinopathy, reflecting its consistent focus on innovation and patient care.
Bayer's strengths emerge from its extensive research capabilities, which allow for the development of advanced therapies and treatment protocols tailored to the Japanese population. The company has made significant investments in partnerships and collaborations to expand its reach and influence in this market further.
Bayer's strong commitment to addressing diabetes-related vision problems is further highlighted through strategic mergers and acquisitions, bolstering its comprehensive offerings and enhancing its market presence. By leveraging its resources and expertise, Bayer aims to provide effective solutions that cater specifically to the needs of patients in Japan suffering from diabetic retinopathy.
The Japan Diabetic Retinopathy Market has witnessed significant developments recently, with a growing emphasis on innovative treatment options and advancements in technology. Notably, companies such as Santen Pharmaceutical and Bayer have been focusing on enhancing their product portfolios to address the increasing diabetes prevalence in Japan.
In terms of recent mergers, Novartis announced the acquisition of a smaller biotech firm in July 2023 to broaden its capabilities in treating retinal diseases, aiming to strengthen its position in the diabetic retinopathy segment. Additionally, Eli Lilly's ongoing collaborations with local healthcare providers emphasize the importance of personalized therapy approaches and the integration of digital health solutions.
As of October 2023, Roche and Regeneron Pharmaceuticals have contributed to rapid growth through their joint research initiatives exploring novel treatment pathways.
The increasing incidence of diabetes-related complications has pushed the market valuation upward, prompting major companies like Otsuka Pharmaceutical and AstraZeneca to enhance their investment in Research and Development, enabling them to stay competitive.
Over the last few years, the Japanese government has also been proactive in addressing diabetic retinopathy awareness, further solidifying the market’s potential.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 344.8(USD Million) |
| MARKET SIZE 2024 | 362.0(USD Million) |
| MARKET SIZE 2035 | 912.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.763% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Santen Pharmaceutical, Bayer, Novartis, Otsuka Pharmaceutical, Eli Lilly, AstraZeneca, Roche, Alcon, Chugai Pharmaceutical, Takeda Pharmaceutical, Samsung Bioepis, AbbVie, Pfizer, HoffmannLa Roche, Regeneron Pharmaceuticals |
| SEGMENTS COVERED | Type, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Aging population healthcare needs, Advanced screening technology adoption, Increased prevalence of diabetes, Rising awareness and education programs, Government funding for eye care initiatives |
| KEY MARKET DYNAMICS | aging population, increasing diabetes prevalence, advancements in treatment technologies, growing awareness campaigns, government healthcare initiatives |
| COUNTRIES COVERED | Japan |
Frequently Asked Questions (FAQ) :
The market is expected to be valued at 362.0 USD Million in 2024.
By 2035, the market is projected to reach a value of 912.0 USD Million.
The market is expected to grow at a CAGR of 8.763% during the forecast period from 2025 to 2035.
The NPDR segment is valued at 162.0 USD Million in 2024 and is expected to grow to 406.0 USD Million by 2035.
The PDR segment is projected to be valued at 200.0 USD Million in 2024 and 506.0 USD Million in 2035.
Key players include Santen Pharmaceutical, Bayer, Novartis, Otsuka Pharmaceutical, and Eli Lilly among others.
The Proliferative Diabetic Retinopathy (PDR) segment holds a significant share of the market.
Rising diabetes prevalence and increasing awareness regarding the disease are major growth drivers.
Challenges include high treatment costs and a lack of trained healthcare professionals.
Current market dynamics are fostering innovations and new treatments in the Japan Diabetic Retinopathy Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
